CN113164599A - 抗pd-l1单克隆抗体治疗癌症的用途 - Google Patents

抗pd-l1单克隆抗体治疗癌症的用途 Download PDF

Info

Publication number
CN113164599A
CN113164599A CN201980081462.1A CN201980081462A CN113164599A CN 113164599 A CN113164599 A CN 113164599A CN 201980081462 A CN201980081462 A CN 201980081462A CN 113164599 A CN113164599 A CN 113164599A
Authority
CN
China
Prior art keywords
seq
antibody
amino acid
acid sequence
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201980081462.1A
Other languages
English (en)
Other versions
CN113164599B (zh
Inventor
张喜全
王训强
赵伟
熊征江
苏楠
吴若男
邵小文
张驰
闫云霞
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Nanjing Shunxin Pharmaceutical Co Ltd
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Nanjing Shunxin Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd, Nanjing Shunxin Pharmaceutical Co Ltd filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Publication of CN113164599A publication Critical patent/CN113164599A/zh
Application granted granted Critical
Publication of CN113164599B publication Critical patent/CN113164599B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

本申请提供抗PD‑L1单克隆抗体治疗癌症的用途,其包括向所述主体施用治疗有效量的PD‑1受体和其配体PD‑L1之间的相互作用的抑制剂,其中抑制剂是抗PD‑L1单抗。

Description

PCT国内申请,说明书已公开。

Claims (36)

  1. PCT国内申请,权利要求书已公开。
CN201980081462.1A 2018-12-24 2019-12-24 抗pd-l1单克隆抗体治疗癌症的用途 Active CN113164599B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2018115813243 2018-12-24
CN201811581324 2018-12-24
PCT/CN2019/127891 WO2020135415A1 (zh) 2018-12-24 2019-12-24 抗pd-l1单克隆抗体治疗癌症的用途

Publications (2)

Publication Number Publication Date
CN113164599A true CN113164599A (zh) 2021-07-23
CN113164599B CN113164599B (zh) 2023-08-01

Family

ID=71127637

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980081462.1A Active CN113164599B (zh) 2018-12-24 2019-12-24 抗pd-l1单克隆抗体治疗癌症的用途

Country Status (2)

Country Link
CN (1) CN113164599B (zh)
WO (1) WO2020135415A1 (zh)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107001463A (zh) * 2014-08-05 2017-08-01 中美冠科生物技术(太仓)有限公司 抗pd‑l1抗体
CN107207593A (zh) * 2014-12-09 2017-09-26 雷纳神经科学公司 抗pd‑1抗体及其使用方法
WO2017210453A1 (en) * 2016-06-02 2017-12-07 Bristol-Myers Squibb Company Pd-1 blockade with nivolumab in refractory hodgkin's lymphoma
CN107667119A (zh) * 2015-05-12 2018-02-06 豪夫迈·罗氏有限公司 用于癌症的治疗和诊断方法
CN108026173A (zh) * 2015-06-12 2018-05-11 百时美施贵宝公司 通过联合阻断pd-1和cxcr4信号传导途径治疗癌症
CN109195989A (zh) * 2016-05-26 2019-01-11 默克专利股份有限公司 用于癌症治疗的pd-1/pd-l1抑制剂

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY193229A (en) * 2015-06-16 2022-09-26 Merck Patent Gmbh Pd-l1 antagonist combination treatments

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107001463A (zh) * 2014-08-05 2017-08-01 中美冠科生物技术(太仓)有限公司 抗pd‑l1抗体
CN107207593A (zh) * 2014-12-09 2017-09-26 雷纳神经科学公司 抗pd‑1抗体及其使用方法
CN107667119A (zh) * 2015-05-12 2018-02-06 豪夫迈·罗氏有限公司 用于癌症的治疗和诊断方法
CN108026173A (zh) * 2015-06-12 2018-05-11 百时美施贵宝公司 通过联合阻断pd-1和cxcr4信号传导途径治疗癌症
CN109195989A (zh) * 2016-05-26 2019-01-11 默克专利股份有限公司 用于癌症治疗的pd-1/pd-l1抑制剂
WO2017210453A1 (en) * 2016-06-02 2017-12-07 Bristol-Myers Squibb Company Pd-1 blockade with nivolumab in refractory hodgkin's lymphoma

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
杨明子;宋玉琴;朱军;: "PD-1/PD-L1在复发/难治经典霍奇金淋巴瘤中的应用进展", 中国医学前沿杂志(电子版), no. 12, pages 6 - 11 *

Also Published As

Publication number Publication date
WO2020135415A1 (zh) 2020-07-02
CN113164599B (zh) 2023-08-01

Similar Documents

Publication Publication Date Title
US12083112B2 (en) Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer
US11866509B2 (en) Humanized antibodies against CEACAM1
JP6783312B2 (ja) がんを処置するためのox40アゴニストおよび4−1bbアゴニストモノクローナル抗体の組み合わせ
JP6586087B2 (ja) Pd−1アンタゴニストとジナシクリブとの組合せでの癌治療
US20160031990A1 (en) Antagonists of pdl-1 and pd-1 for the treatment of hpv-negative cancers
TW202233239A (zh) 用於治療非小細胞肺癌之抗b7-h1及抗ctla-4抗體
WO2021228178A1 (en) Compositions and methods for treating cancer
WO2020211804A1 (zh) 抗pd-1抗体在制备治疗实体瘤的药物中的用途
CN113318226A (zh) 抗pd-l1抗体联合放射性射线治疗肺癌的方法
CN111973739A (zh) 抗pd-l1单克隆抗体治疗癌症的用途
WO2021155840A1 (zh) 抗pd-1抗体在治疗恶性肿瘤中的用途
CN113365659B (zh) 抗pd-l1抗体治疗头颈癌的用途
US11427647B2 (en) Polynucleotides encoding humanized antibodies against CEACAM1
CN113164599B (zh) 抗pd-l1单克隆抗体治疗癌症的用途
CN113117072A (zh) 喹啉衍生物与pd-1单抗的药物组合
US20240092934A1 (en) Assessment of ceacam1 expression on tumor infiltrating lymphocytes
WO2024208253A1 (en) Compositions and methods for treating solid tumors with anti-btla as combination therapy

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
CB03 Change of inventor or designer information
CB03 Change of inventor or designer information

Inventor after: Zhang Xiquan

Inventor after: Wang Xunqiang

Inventor after: Zhao Wei

Inventor after: Xiong Zhengjiang

Inventor after: Su Nan

Inventor after: Wu Ruonan

Inventor after: Shao Xiaowen

Inventor after: Zhang Chi

Inventor after: Yan Yunxia

Inventor before: Zhang Xiquan

Inventor before: Wang Xunqiang

Inventor before: Zhao Wei

Inventor before: Xiong Zhengjiang

Inventor before: Su Nan

Inventor before: Wu Ruonan

Inventor before: Shao Xiaowen

Inventor before: Zhang Chi

Inventor before: Yan Yunxia

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant